Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 94 filers reported holding Y-MABS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $199,214 | -78.8% | 36,553 | -73.6% | 0.00% | -83.3% |
| Q2 2023 | $940,741 | +229.3% | 138,548 | +143.0% | 0.01% | +200.0% |
| Q1 2023 | $285,696 | +49.5% | 57,025 | +45.6% | 0.00% | +100.0% |
| Q4 2022 | $191,096 | +32.7% | 39,159 | +291.6% | 0.00% | 0.0% |
| Q3 2022 | $144,000 | -10.0% | 10,000 | -5.1% | 0.00% | 0.0% |
| Q2 2022 | $160,000 | +5.3% | 10,542 | -17.5% | 0.00% | 0.0% |
| Q1 2022 | $152,000 | -64.2% | 12,783 | -14.1% | 0.00% | -80.0% |
| Q3 2021 | $425,000 | +60.4% | 14,884 | +177.9% | 0.01% | +25.0% |
| Q4 2020 | $265,000 | +2108.3% | 5,356 | +930.0% | 0.00% | – |
| Q2 2019 | $12,000 | -78.2% | 520 | -75.0% | 0.00% | -100.0% |
| Q3 2018 | $55,000 | – | 2,082 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 216,916 | $6,191,000 | 3.86% |
| Sofinnova Investments, Inc. | 2,194,278 | $62,625,000 | 3.71% |
| MPM BioImpact LLC | 452,970 | $12,928,000 | 2.00% |
| Soleus Capital Management, L.P. | 265,700 | $7,583,000 | 1.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 452,110 | $12,903,000 | 1.17% |
| ORACLE INVESTMENT MANAGEMENT INC | 315,642 | $9,008,000 | 1.12% |
| First Light Asset Management, LLC | 577,663 | $16,487,000 | 1.09% |
| Lombard Odier Asset Management (Switzerland) SA | 352,839 | $10,070,000 | 0.62% |
| Cormorant Asset Management, LP | 500,000 | $14,270,000 | 0.58% |
| Artal Group S.A. | 400,000 | $11,416,000 | 0.26% |